Treprostinil (Tyvaso DPI) vs Treprostinil (Yutrepia, Liquidia)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Treprostinil (Tyvaso DPI)
Marketed by United Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Treprostinil (Yutrepia, Liquidia)
Marketed by Liquidia Corporation
NCT03399604 · Phase 3 · completed
The study was an open-label, single-group trial with 121 participants and no placebo or active comparator. Its primary endpoint was treatment-emergent and serious adverse events, rather than a controlled clinical efficacy outcome, so the findings provide limited evidence about the treatment’s comparative effectiveness.
Next expected readout: May 2027 · NCT07759804 (registry estimate)
Reported efficacy
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): LIQ861 Inhaled Treprostinil 121 Participants (not_applicable)
Result source: NCT03399604
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Treprostinil (Tyvaso DPI): 4 of 4 rows · Treprostinil (Yutrepia, Liquidia): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Treprostinil (Tyvaso DPI) | Treprostinil (Yutrepia, Liquidia) |
|---|---|---|
| Dropout rate | —64 mcga NCT03950739 · Phase 1 · registry result, not featured evidence show 6 more results—64 mcg NCT03950739 · Phase 1 · registry result, not featured evidence —48 mcg NCT03950739 · Phase 1 · registry result, not featured evidence —48 mcg NCT03950739 · Phase 1 · registry result, not featured evidence —32 mcg NCT03950739 · Phase 1 · registry result, not featured evidence —32 mcg NCT03950739 · Phase 1 · registry result, not featured evidence 3.9%Tyvaso to TreT NCT03950739 · Phase 1 · registry result, not featured evidence | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result24%LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Discontinued due to AEs | —64 mcga NCT03950739 · Phase 1 · registry result, not featured evidence show 6 more results—64 mcg NCT03950739 · Phase 1 · registry result, not featured evidence —48 mcg NCT03950739 · Phase 1 · registry result, not featured evidence —48 mcg NCT03950739 · Phase 1 · registry result, not featured evidence —32 mcg NCT03950739 · Phase 1 · registry result, not featured evidence —32 mcg NCT03950739 · Phase 1 · registry result, not featured evidence 3.9%Tyvaso to TreT NCT03950739 · Phase 1 · registry result, not featured evidence | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Serious AEs | 57.1%64 mcga NCT03950739 · Phase 1 · registry result, not featured evidence show 6 more results4.5%64 mcg NCT03950739 · Phase 1 · registry result, not featured evidence 46.2%48 mcg NCT03950739 · Phase 1 · registry result, not featured evidence 3.7%48 mcg NCT03950739 · Phase 1 · registry result, not featured evidence 50%32 mcg NCT03950739 · Phase 1 · registry result, not featured evidence 0%32 mcg NCT03950739 · Phase 1 · registry result, not featured evidence —Tyvaso to TreT NCT03950739 · Phase 1 · registry result, not featured evidence | 12.4%LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Most frequent reported AEs | 64 mcga fatigue 23.8% arthralgia 19% back pain 19% NCT03950739 · Phase 1 · registry result, not featured evidence show 5 more results64 mcg cough 31.8% headache 18.2% diarrhoea 9.1% NCT03950739 · Phase 1 · registry result, not featured evidence 48 mcg dyspnoea 38.5% covid-19 26.9% dizziness 23.1% NCT03950739 · Phase 1 · registry result, not featured evidence 48 mcg cough 40.7% headache 14.8% dyspnoea 7.4% NCT03950739 · Phase 1 · registry result, not featured evidence 32 mcg dyspnoea 100% headache 100% nausea 100% NCT03950739 · Phase 1 · registry result, not featured evidence 32 mcg acute respiratory failure 0% anaemia 0% anxiety 0% NCT03950739 · Phase 1 · registry result, not featured evidence | cough 33.9% headache 19% upper respiratory tract infection 14.9% NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Treprostinil (Tyvaso DPI)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (Tyvaso DPI)'s landscape · Treprostinil (Yutrepia, Liquidia)'s landscape